LY03020 / Luye Group - LARVOL DELTA

Luye Pharma...announced that the China Phase II clinical trial of its self-developed innovative drug LY03020 has completed enrollment of the first patient. (iis.aastocks.com)

Enrollment open • Alzheimer's Disease • Psychiatry • Schizophrenia

A Phase 2 Study to Evaluate the Efficacy and Safety of LY03020 in Acutely Psychotic Participants With Schizophrenia (clinicaltrials.gov) - P2 | N=160 | Not yet recruiting | Sponsor: Luye Pharma Group Ltd.

New P2 trial • CNS Disorders • Psychiatry • Schizophrenia

A Food Effect Study of LY03020 in Healthy Subjects (clinicaltrials.gov) - P1 | N=16 | Active, not recruiting | Sponsor: Luye Pharma Group Ltd.

New P1 trial • Alzheimer's Disease • CNS Disorders • Psychiatry • Schizophrenia

A Phase 1 MAD Study to Evaluate the Safety and Tolerability of LY03020 (clinicaltrials.gov) - P1 | N=40 | Recruiting | Sponsor: Luye Pharma Group Ltd.

New P1 trial • Alzheimer's Disease • CNS Disorders • Psychiatry • Schizophrenia

A Study Assessing the Safety and Tolerability of LY03020 in Chinese Healthy Subjects (clinicaltrials.gov) - P1 | N=66 | Completed | Sponsor: Luye Pharma Group Ltd. | Not yet recruiting ➔ Completed | Trial completion date: Aug 2025 ➔ Feb 2025

Trial completion • Trial completion date • Alzheimer's Disease • CNS Disorders • Psychiatry • Schizophrenia

A Study Assessing the Safety and Tolerability of LY03020 in Chinese Healthy Subjects (clinicaltrials.gov) - P1 | N=66 | Not yet recruiting | Sponsor: Luye Pharma Group Ltd.

New P1 trial • Alzheimer's Disease • CNS Disorders • Psychiatry • Schizophrenia